MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.130
-0.080
-2.49%
After Hours: 3.050 -0.08 -2.56% 18:30 04/16 EDT
OPEN
3.170
PREV CLOSE
3.210
HIGH
3.230
LOW
3.030
VOLUME
635.47K
TURNOVER
--
52 WEEK HIGH
17.95
52 WEEK LOW
3.030
MARKET CAP
111.81M
P/E (TTM)
-3.0189
1D
5D
1M
3M
1Y
5Y
Global Mesenchymal Stem Cells Market Analysis 2021, Size Estimation, Major Manufacturers with Business Share, Total Revenues, Product Scope, Development Status and Opportunities till 2026
Apr 16, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" Global “Mesenchymal Stem Cells Market” 2021...
The Express Wire · 1d ago
Induced Pluripotent Stem Cells Market Trends 2021 Analysis By Industry Statistics, Progression Status, Emerging Demands, Business Opportunity, Share and Forecast To 2026 Says Precision Reports
Apr 14, 2021 (The Expresswire) -- Global “Induced Pluripotent Stem Cells Market” research report offers qualitative and quantitative insights in relation to...
The Express Wire · 2d ago
TENX: HELP Results & New Asset to Boot
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT
Benzinga · 3d ago
Global Mesenchymal Stem Cells Market Size 2021 By Share, Growth Analysis, Industry Share, End-User Demand, Size Estimation, Growth Factors, Production, Industry Statistics, Overview, and Forecast Report till 2026
The Express Wire · 3d ago
Adult Stem Cells Market Size 2021 Growing Rapidly with Recent Developments, Industry Share, Trends, Demand, Revenue, Key Findings, Latest Technology, Industry Expansion Strategies till 2026
Apr 13, 2021 (The Expresswire) -- The Global “Adult Stem Cells Market” 2021 research report is a historical overview and in-depth study on the current and...
The Express Wire · 3d ago
Human Embryonic Stem Cells Market 2021 Size, Growth, Share, Global Industry Current Trends, Analysis of Top Companies, Application, Development and Forecast to 2025 Research Report
Apr 11, 2021 (The Expresswire) -- Global “ Human Embryonic Stem Cells Market” report provides a detailed analysis of global size, share, regional and...
The Express Wire · 6d ago
Global Epithelial Stem Cells Market Growth, Status and Outlook Research Report 2021-2026
Apr 08, 2021 (Heraldkeepers) -- The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size...
Heraldkeepers · 04/08 09:12
Do Institutions Own Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
A look at the shareholders of Brainstorm Cell Therapeutics Inc. ( NASDAQ:BCLI ) can tell us which group is most...
Simply Wall St. · 04/07 07:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCLI. Analyze the recent business situations of Brainstorm Cell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCLI stock price target is 11.50 with a high estimate of 12.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 114
Institutional Holdings: 8.62M
% Owned: 24.12%
Shares Outstanding: 35.72M
TypeInstitutionsShares
Increased
25
1.12M
New
28
1.28M
Decreased
21
290.71K
Sold Out
17
589.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Director
Jacob Frenkel
President
Ralph Kern
Chief Executive Officer
Chaim Lebovits
Vice Chairman/Director
Irit Arbel
Chief Financial Officer/Executive Vice President/Treasurer
Preetam Shah
Chief Operating Officer/Executive Vice President
David Setboun
Executive Vice President/Director
Uri Yablonka
Executive Vice President
Stacy Lindborg
Executive Vice President
Anthony Waclawski
Other
Arturo Araya
Director
Sankesh Abbhi
Independent Director
June Almenoff
Independent Director
Anthony Polverino
Independent Director
Malcolm Taub
No Data
  • All
  • Financials
  • Insiders
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.